Erwin Bottinger This is Me

 Web References

1. 1. Trilogy Instrument Installed at Mount Sinai November 9, 2004 - News

   www.bio-itworld.com/news/11090 - [Cached]

   Published on: 11/9/2004   Last Visited: 11/9/2004

   Erwin Bottinger, Vice-Chair for Research at the Bronfman Department of Medicine, told Bio-IT World he anticipates using Trilogy in "a whole range of applications," including "quantitative analysis of transcript levels in samples… genotyping applications, micro-RNA quantitative analysis, quantification of proteins with antibodies, and protein modifications. We're interested in developing quantitative assays for the phosphorylation state of proteins."
   
   The U.S. Genomics Trilogy platform ingeniously takes a solution of DNA or other nucleic acids and unwinds the molecules, enabling them to pass in linear fashion across a laser detector. The technology has been frequently cited in recent years in regard to discussions about the "$1,000 genome," but U.S. Genomics has downplayed that lately, stressing instead the technology's assay applications in the field of single molecule biology.
   
   At Mount Sinai, Bottinger and colleagues perform numerous screens of gene expression in different disease conditions. He expects that Trilogy studies "would follow on a number of leads in microarray screens, in experimental samples and patient samples, to see how the quantitative analysis relates to phenotypic outcomes."
   
   Critical Issue The "critical issue" of reliable, quantitative analysis "will be very important in the future," predicts Bottinger. One of the potential benefits of Trilogy, he says, is that "there's no amplification step between readout and sample.
   ...
   "We have a group of experienced state-of-the-art investigators who are working together as an interest group, and we're interactive with U.S. Genomics," says Bottinger. "We're sharing our experience with the platform."